Fig. 3.

Primary and supportive outcome results comparing Amubarvimab/romlusevimab (A/R) versus placebo treatment. Weighted Model 1 = IPW model based on time interval. Weighted Model 2 = IPW model based on time interval, baseline characteristics and their interactions with time interval. Weighted Model 3 = IPW model based on time interval, baseline characteristics, day 22–28 symptom variable, and their interactions with time interval. Weighted Model 3a = IPW model based on time interval, baseline characteristics, day 22–28 symptom variable, whether or not a participant was hospitalized prior to week 36, and their interactions with time interval.